Takeda Pharmaceutical Co. Ltd. has selected leon-nanodrugs GmbH’s MicroJet Reactor for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products.
 
Under the companies’ collaboration, leon will support Takeda`s formulation efforts to optimize solubility, bioavailability and stability for one of Takeda’s current pipeline products for drug delivery using leon’s nanotechnology platform – MicroJet Reactor. The platform can be used from early compound screening to production of market batches. Results from this study could potentially result in a long-term collaboration and additional compounds may also be considered.
 
leon’s MJR technology offers reformulation options that address API’s that are poorly soluble in water, and can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc.
 
Dr. Michael Mehler, chief executive officer of leon-nanodrugs GmbH said, “We are very pleased and proud that Takeda selected our MJR technology for a feasibility assessment with one of their compounds in development. It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide.”